Dechra Pharmaceuticals - 股票

Dechra Pharmaceuticals 市值 2024

Dechra Pharmaceuticals 市值

4.39 亿 GBP

股票代码

DPH.L

ISIN

GB0009633180

WKN

578968

在2024年,Dechra Pharmaceuticals的市值为4.39 亿 GBP,比前一年的市值3.36 亿 GBP增长了30.41%

Dechra Pharmaceuticals 市值 历史

营业额 (undefined GBP)毛利率 (%)利润 (undefined GBP)
2028e1.0740,00230.69
2027e142,83179.94
2026e0.9843,71203.81
2025e0.9346,38166.98
2024e0.8550,47147.77
20230.7656,41-27.9
20220.6856,5158.2
20210.6156,8955.5
20200.5256,6133.9
20190.4857,7430.9
20180.4155,8836.1
20170.3654,5426.11
20160.2555,9512.67
20150.257,0819.46
20140.1955,6359
20130.1953,2217.9
20120.4323,3111.7
20110.3922,7114.1
20100.3721,8213.2
20090.3521,0611.3
20080.317,618.3
20070.2514,548.8
20060.2314,327.6
20050.2114,276.3
20040.1913,605.1

Dechra Pharmaceuticals Aktienanalyse

Dechra Pharmaceuticals在做什么?

Dechra Pharmaceuticals PLC is a British company specializing in animal medicine. It was founded in 1997 and has experienced remarkable growth since then. Dechra is listed on the London Stock Exchange and has its headquarters in Northwich, Cheshire, UK. Dechra builds its business models on a broad portfolio of products and services. The company is primarily focused on the development and sale of pharmaceuticals and diagnostics tailored to the needs of veterinarians and pet owners. The company has an extensive range of animal medicines, divided into categories such as antibiotics, painkillers, and anti-inflammatory drugs. Dechra operates three major business segments that drive its growth: the veterinary medicines business, the diagnostics business, and the specialty pharma business. The veterinary medicines business is the core of Dechra's operations. Here, the company produces products that can be used on livestock and companion animals. Dechra dominates the animal medicine market in Europe and has also established itself in the field of animal health in the US. The diagnostics business is another important segment that focuses on diagnostics and tests to quickly and effectively diagnose animal diseases. These products are primarily sold to veterinarians and veterinary laboratories. Dechra's specialty pharma business focuses on the production of specialty drugs tailored to a specific animal species or a specific disease that affects rarer species. Producing such medications generally requires higher expertise and also results in higher profitability due to typically lower competition. In recent years, Dechra has accelerated its presence and growth through targeted acquisitions. These acquisitions have expanded both Dechra's portfolio and geographic reach. In 2014, Dechra acquired US-based Genera N.A., a specialized pharmaceutical company producing animal medicines. With the acquisition of Genera, Dechra was able to strengthen its presence in the US animal medicine market. The company has also made acquisitions in Europe, such as the acquisition of Eurovet Animal Health in 2020. Eurovet is a Netherlands-based company specializing in animal health products and covers important market regions in Europe. The acquisition of Eurovet has allowed Dechra to strengthen its presence in Germany and Scandinavia. In summary, Dechra Pharmaceuticals PLC is one of the leading companies in the animal medicine industry. The company has maintained its reputation by creating innovative products and services based on the highest manufacturing and operational standards. The company is committed to continuing to provide value to veterinarians and pet owners while improving the health and well-being of animals. Dechra Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

市值的详细信息

Dechra Pharmaceuticals的市值分析

Dechra Pharmaceuticals的市值代表了公司在美元中的所有未流通股票的总市场价值。它是通过将公司的未流通股票数乘以每股的当前市场价格来计算的。这个指标是一个关于公司规模,实力和整体市场价值的重要指标。

年度对比

Dechra Pharmaceuticals市值的年度对比能为投资者和分析师提供公司的增长和估值趋势的观察视角。一次增加可能表明市场信任和业务扩展,而一次减少可能表明市场价值下降或业务衰退。

对投资的影响

Dechra Pharmaceuticals的市值在投资决策中发挥了重要的作用。它帮助投资者评估公司的风险以及收益水平。大公司通常被视为更稳定,但可能提供较低的增长潜力,而小公司可能提供明显的增长前景,但可能风险较高。

市值波动的解读

Dechra Pharmaceuticals的市值波动可能由多种因素引起,包括股票价格的变动、未流通股票数的变化以及市场情绪的变化。了解这些波动有助于投资者评估公司在竞争环境中的当前位置和未来潜力。

关于Dechra Pharmaceuticals股票的常见问题

Dechra Pharmaceuticals的市值目前是多少?

Dechra Pharmaceuticals的当前市值为4.39 亿 GBP。

什么是市值?

市值(英语:market capitalisation,简称market cap,也叫做股票市场总值或股票总价值)是所有已在股票市场上市的公司如Dechra Pharmaceuticals的股票总值。

Dechra Pharmaceuticals的市值在过去几年里发展如何?

与去年相比,Dechra Pharmaceuticals的市值增长了30.41% 上升。

市值对投资者意味着什么?

一个公司的市值反映了市场对上市公司股权价值的当前共识。

为什么市值是投资者的重要指标?

一家公司的市值反映了市场对上市公司股权价值的当前共识。它由公司股票的供需决定。因此,市值在很大程度上受到股市对公司未来盈利能力的期望影响,可能会出现强烈波动。

为什么市值会波动?

市值会随着股价的波动而波动,因为市值是由当前价格和流通股数量计算得出的。

Dechra Pharmaceuticals的评估中市值起着什么样的作用?

为了能够比较企业的价值,除了市值之外,了解企业的净债务也是有帮助的。如果有人要购买整个企业,那么在购买时也会同时购买企业的债务。企业价值或者说企业价值是企业或股份有限公司的总价值。企业的净负债会计入其市值。

Dechra Pharmaceuticals的市值是否影响其表现?

没有任何可证实的长期证据或研究表明,具有特定市值(无论是超大盘/大盘/中盘/小盘)的股票会长期产生明显高于其他股票的收益。偶尔会有一些小型研究(股票少,投资期短),表明某些类别的表现更好或风险更高,但没有任何研究1.具有决定性的(因果关系不清楚,实验不可重复)或2.普遍适用(不能概括,因为样本和时间段太小)。

Dechra Pharmaceuticals的市值是否影响指数?

一些股票指数使用市值作为指数权重。市值较高的股票在指数中的权重也会较高。这与等权重指数(所有股票有相同的权重)和流通股权重指数(市值权重,但只计算流通在外的股票数量)相对立。

Dechra Pharmaceuticals支付多少股息?

在过去的12个月中,Dechra Pharmaceuticals支付了0.25 GBP 的股息。这相当于大约0.65 %的股息收益率。在未来的12个月内,Dechra Pharmaceuticals预计将支付0.25 GBP的股息。

Dechra Pharmaceuticals的股息收益率有多高?

Dechra Pharmaceuticals当前的股息收益率为0.65 %。

Dechra Pharmaceuticals什么时候支付股息?

Dechra Pharmaceuticals按季度支付股息。这些股息将在, , , 月份分发。

Dechra Pharmaceuticals的股息有多安全?

Dechra Pharmaceuticals 在过去25年里每年都支付了股息。

Dechra Pharmaceuticals的股息有多高?

预计未来12个月的股息将达到0.25 GBP。这相当于0.65 %的股息收益率。

Dechra Pharmaceuticals位于哪个行业?

Dechra Pharmaceuticals 被分配到“健康”板块。

Wann musste ich die Aktien von Dechra Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

要获得Dechra Pharmaceuticals在支付的0.125 GBP的最后一笔股息,你必须在的除息日之前持有该股票于你的账户中。

Dechra Pharmaceuticals最后一次支付股息是什么时候?

上一次股息发放日期为。

Dechra Pharmaceuticals在2023年的股息是多少?

在2023年,Dechra Pharmaceuticals 分配了0.449 GBP作为股息。

Dechra Pharmaceuticals 的股息是以哪种货币支付的?

Dechra Pharmaceuticals的股息将以GBP的形式分配。

股票储蓄计划为投资者提供了一种吸引人的方法,可以长期累积财富。主要优势之一是所谓的成本平均效应:通过定期投入固定金额于股票或股票基金,当价格低时自动买入更多份额,价格高时买入较少,这可能随着时间带来更优惠的平均每份成本。此外,股票储蓄计划还允许小额投资者接触到高价股票,因为他们可以用很小的金额参与其中。定期投资也促进了一种纪律投资策略,并有助于避免情绪化的决策,如冲动买卖。除此之外,投资者还能从股票的潜在增值以及可以再投资的股息分红中获益,这增强了复利效应,从而增加了投资资本的增长。

Dechra Pharmaceuticals 股票在以下供应商处可进行定投计划:Trade Republic

Andere Kennzahlen von Dechra Pharmaceuticals

我们对Dechra Pharmaceuticals 营业额股票的股票分析包括重要的财务指标,如收入、利润、市盈率、市销率、息税折旧摊销前利润,以及有关股息的信息。此外,我们还研究了诸如股票、市值、债务、股东权益和Dechra Pharmaceuticals 营业额的负债等方面。如果您在寻找关于这些主题的更详细信息,我们在子页面上提供了详细的分析: